Evonik’s Pricing Power Meets Rising Labor Costs

As union negotiations for higher wages in Germany’s chemical sector continue, Evonik has received a surprising vote of confidence from the market. Analysts at Barclays have upgraded their rating on the specialty chemicals group, highlighting unexpected strength in a previously troublesome business segment. This creates a compelling narrative of emerging pricing power potentially offsetting looming cost pressures.

Solid Operational Foundation and Future Targets

Operationally, Evonik has maintained a robust position. The company closed its 2025 fiscal year with an adjusted EBITDA of €1.87 billion and generated a strong free cash flow of €695 million. For the current year, management is targeting an operating result in the range of €1.7 to €2.0 billion.

Looking further ahead, a new dividend policy will take effect starting in the 2026 fiscal year. The policy commits to a payout ratio of 40% to 60% of the group’s adjusted net income. Achieving the medium-term goal of lifting the capital return rate from a recent 6.1% to 11% will require two key developments: a moderate outcome from the ongoing wage talks and the successful execution of a global workforce reduction plan.

Should investors sell immediately? Or is it worth buying Evonik?

Efficiency Drive Confronts Wage Negotiations

This planned job reduction is central to the “Evonik Tailor Made” transformation program, which aims to deliver annual savings of €400 million by the end of 2026. Management notes that approximately 80% of these savings are expected to come from cutting 2,000 positions worldwide. Consequently, a significant wage increase resulting from the current negotiations between the employer association BAVC and the union IGBCE could substantially erode these hard-won efficiency gains.

Methionine Emerges as a Key Profit Driver

The catalyst for Barclays’ upgrade is a positive shift in the methionine market. This feed additive, where Evonik is the global leader, is seeing increased demand for European production capacity. Supply disruptions in Asia, driven by geopolitical tensions, are redirecting orders. Seizing this opportunity, the Essen-based company successfully implemented a global 10% price increase for its MetAMINO product.

In response, Barclays analyst Anil Shenoy raised his rating on Evonik shares to “Overweight” on Tuesday and increased the price target from €16 to €17. The stock, which closed at €14.81 yesterday, has already gained approximately 11% since the start of the year. Furthermore, a current RSI reading of 28.9 indicates a technically oversold condition, which could provide near-term support for the more optimistic analyst outlook.